{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:36:09Z","timestamp":1791894969883,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In clinical practice, 5\u03b1-reductase inhibitors (5ARIs) and \u03b1-blockers (ABs) are commonly prescribed for benign prostatic hyperplasia (BPH). However, evidence supporting rational selection of combination therapy remains limited. The FDA Adverse Event Reporting System (FAERS) database is a valuable resource for investigating the safety profile and concomitant use patterns of these medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed adverse events (AEs) from 2004Q1 to 2024Q4 in BPH patients receiving combination therapy with 5ARIs and ABs. Drug\u2013drug interactions (DDIs) were evaluated using five established algorithms, and disproportionality analysis was performed to identify targeted AEs associated with these medication classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Disproportionality analysis revealed that 5ARIs were predominantly linked to sexual dysfunction, whereas ABs were primarily associated with renal impairment. Additionally, certain drugs showed strong associations with physical discomfort, neurological symptoms, hypotension, and shock-related events. DDI analysis indicated that co-administration of 5ARIs and ABs may exacerbate both renal impairment and sexual dysfunction. Notably, the combination of tamsulosin and dutasteride significantly prolonged the time to resistance to dutasteride in BPH patients. These findings are consistent with prior clinical studies and align well with existing clinical and epidemiological evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results provide meaningful insights into optimizing drug selection in BPH treatment. We recommend close monitoring of relevant safety parameters when implementing combination therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1870053","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:28:10Z","timestamp":1781497690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug combination choices of 5\u03b1-reductase inhibitors and \u03b1-blockers in patients with benign prostatic hyperplasia: a study based on the FAERS database"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinqin","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University First Hospital","place":["Beijing, China"]},{"name":"The Institution of Urology, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital","place":["Beijing, China"]},{"name":"The Institution of Urology, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuijian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital","place":["Beijing, China"]},{"name":"The Institution of Urology, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital","place":["Beijing, China"]},{"name":"The Institution of Urology, Peking University","place":["Beijing, China"]},{"name":"Department of Urology, The First Affiliated Hospital of Henan University","place":["Kaifeng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/nrdp.2016.31","article-title":"Benign prostatic hyperplasia","volume":"2","author":"Chughtai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s41182-025-00770-0","article-title":"Global, regional, and national lifetime risks of developing benign prostatic hyperplasia in men aged over 40: a population-based cross-sectional study from 1990 to 2021","volume":"53","author":"Chen","year":"2025","journal-title":"Trop Med Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","article-title":"Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","article-title":"The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"3","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bju.15229","article-title":"Benign prostatic hyperplasia \u2013 what do we know?","volume":"127","author":"Devlin","year":"2021","journal-title":"BJU Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/14656566.2023.2237406","article-title":"Overview of current pharmacotherapeutic options in benign prostatic hyperplasia","volume":"24","author":"Koudonas","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40266-025-01198-1","article-title":"Combination pharmacotherapy for benign prostatic hyperplasia: evaluation of existing literature on combination therapies for lower urinary tract symptoms associated with BPH","volume":"42","author":"Papet","year":"2025","journal-title":"Drugs Aging"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4111\/kju.2013.54.2.100","article-title":"Effect of patient-optimized doses of tamsulosin on erectile function in men with erectile dysfunction and lower urinary tract symptoms","volume":"54","author":"Jo","year":"2013","journal-title":"Korean J Urol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11154-015-9319-y","article-title":"Adverse effects of 5\u03b1-reductase inhibitors: what do we know, don't know, and need to know?","volume":"16","author":"Traish","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756287215607419","article-title":"Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia","volume":"8","author":"Dimitropoulos","year":"2016","journal-title":"Ther Adv Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5070\/D32311037240","article-title":"Sexual side effects of 5-\u03b1-reductase inhibitors finasteride and dutasteride: a comprehensive review","volume":"23","author":"Fertig","year":"2017","journal-title":"Dermatol Online J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"f6320","DOI":"10.1136\/bmj.f6320","article-title":"Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology","volume":"347","author":"Bird","year":"2013","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2147\/ciia.2006.1.4.389","article-title":"Doxazosin in the treatment of benign prostatic hypertrophy: an update","volume":"1","author":"Wilt","year":"2006","journal-title":"Clin Interv Aging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","article-title":"Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database","volume":"111","author":"Liu","year":"2025","journal-title":"Int J Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front Drug Saf Regul"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (standards for QUality improvement reporting excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100082","DOI":"10.70389\/PJS.100082","article-title":"Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1111\/dom.16491","article-title":"Post-marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: a disproportionality analysis using the FDA adverse event reporting system (FAERS) database","volume":"27","author":"Ezeja","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/js9.0000000000003314","article-title":"Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody-drug conjugates using FAERS database","volume":"112","author":"Zheng","year":"2025","journal-title":"Int J Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"18459","DOI":"10.1038\/s41598-023-45783-z","article-title":"The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome","volume":"13","author":"Kyotani","year":"2023","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/JU.0000000000000499","article-title":"Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the urologic diseases in America project","volume":"203","author":"Welliver","year":"2020","journal-title":"J Urol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.prnil.2021.08.002","article-title":"Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: a nationwide population-based cohort study","volume":"9","author":"Kim","year":"2021","journal-title":"Prostate Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00345-020-03429-z","article-title":"Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study","volume":"39","author":"Ayele","year":"2021","journal-title":"World J Urol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jsxm.2016.07.006","article-title":"Effect of 5\u03b1-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials","volume":"13","author":"Liu","year":"2016","journal-title":"J Sex Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/andr.12353","article-title":"Sexual dysfunction in subjects treated with inhibitors of 5\u03b1-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis","volume":"5","author":"Corona","year":"2017","journal-title":"Andrology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/14656566.2020.1817382","article-title":"Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects","volume":"22","author":"La Vignera","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1292163","DOI":"10.3389\/fphar.2024.1292163","article-title":"Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events","volume":"15","author":"Huo","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e65872","DOI":"10.2196\/65872","article-title":"Detection of clinically significant drug-drug interactions in fatal Torsades de pointes: disproportionality analysis of the Food and Drug Administration adverse event reporting system","volume":"27","author":"Ji","year":"2025","journal-title":"J Med Internet Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ucl.2021.12.003","article-title":"Medical treatment of benign prostatic hyperplasia","volume":"49","author":"Plochocki","year":"2022","journal-title":"Urol Clin North Am"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.euf.2020.12.013","article-title":"Prostatic urethral lift versus medical therapy: examining the impact on sexual function in men with benign prostatic hyperplasia","volume":"8","author":"Roehrborn","year":"2022","journal-title":"Eur Urol Focus"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2134427","DOI":"10.1001\/jamanetworkopen.2021.34427","article-title":"Assessment of frailty and association with progression of benign prostatic hyperplasia symptoms and serious adverse events among men using drug therapy","volume":"4","author":"Bauer","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1870053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:28:17Z","timestamp":1781497697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1870053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1870053"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1870053","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1870053"}}